BioStar Technology International, LLC
Letter data
- Company
- BioStar Technology International, LLC
- Recipient
- Ulysses L. Sheretov | President | BioStar Technology International, LLC | BioStar Technology International, LLC | 2912 Colorado Blvd | Los Angeles | , | CA | 90041 | United States
- Issue date
- 2018-12-14
- Posted date
- Not available
- FDA office
- United States
- Subject
- Not available
- Product
- Not available
- CMS ID
- 512757
- Reference number
- WL #24-17
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
BioStar Technology International, LLC
MARCS-CMS 512757 —
December 14, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
United Parcel Service
Reference #:
WL #24-17 Close-Out Letter
Recipient:
Recipient Name
Ulysses L. Sheretov
Recipient Title
President
BioStar Technology International, LLC
BioStar Technology International, LLC
2912 Colorado Blvd
Los Angeles
,
CA
90041
United States
Issuing Office:
United States
Dear Mr. Sheretov:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter WL # 24-15 issued April 17, 2017. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Compliance Branch Director
Office of Human and Animal Food
Division of Human and Animal FeedWest 5
Content current as of:
02/04/2019